Follow
"Within the confines of the traditional clinical research model, studying novel treatments for rare cancer subtypes is challenging — particularly with respect to patient engagement, financial burden and timeliness. In this issue of Nature Medicine, Liu et al. describe a novel trial design that positions the patient at the focal point of clinical investigation, while exploring the safety and efficacy of first-line pyrotinib in patients with metastatic HER2+ NSCLC"
